KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Cash & Equivalents (2016 - 2026)

Emergent BioSolutions has reported Cash & Equivalents over the past 17 years, most recently at $160.3 million for Q1 2026.

  • For Q1 2026, Cash & Equivalents rose 7.51% year-over-year to $160.3 million; the TTM value through Mar 2026 reached $160.3 million, up 7.51%, while the annual FY2025 figure was $205.4 million, 106.43% up from the prior year.
  • Cash & Equivalents for Q1 2026 was $160.3 million at Emergent BioSolutions, down from $205.4 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $642.6 million in Q4 2022 and troughed at $69.7 million in Q2 2024.
  • A 5-year average of $224.8 million and a median of $160.3 million in 2026 define the central range for Cash & Equivalents.
  • Biggest five-year swings in Cash & Equivalents: crashed 82.62% in 2023 and later surged 283.5% in 2025.
  • Year by year, Cash & Equivalents stood at $642.6 million in 2022, then crashed by 82.62% to $111.7 million in 2023, then dropped by 10.92% to $99.5 million in 2024, then skyrocketed by 106.43% to $205.4 million in 2025, then decreased by 21.96% to $160.3 million in 2026.
  • Business Quant data shows Cash & Equivalents for EBS at $160.3 million in Q1 2026, $205.4 million in Q4 2025, and $245.5 million in Q3 2025.